Novo Nordisk AS is preparing to file an sNDA with FDA and European regulators for the glucagon-like peptide-1 (GLP-1) agonist Victoza (liraglutide) this fall to incorporate new data highlighting the drug’s cardiovascular benefits.
The Danish diabetes specialist presented positive data from the LEADER cardiovascular outcomes trial, testing Victoza versus placebo in patients with...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?